Experimental cocktail aims to tackle Hard-to-Treat head and neck cancer
NCT ID NCT06308913
First seen Apr 23, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-phase trial is testing a new combination of an experimental drug (INCB081776), an immunotherapy (pembrolizumab), and radiation therapy in 10 people with advanced head and neck cancer that has spread or come back. The main goal is to check safety and side effects, while also seeing if the treatment can shrink tumors. Because it is a very small pilot study, the results will only show whether this approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UW Carbone Cancer Center
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB081776 (an experimental drug) combined with pembrolizumab (an immunotherapy) and palliative radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced head and neck cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, small pilot study with only 10 participants, focused mainly on safety. The experimental drug may cause side effects, and it is unknown whether the combination will effectively shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.